Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab [0.03%]
基线C反应蛋白及其在接受派姆单抗作为复发/转移性头颈部肿瘤一线治疗时的变化可预测患者的预后及疗效
Markus Haas,Alexander Lein,Thorsten Fuereder et al.
Markus Haas et al.
Purpose: First-line immune checkpoint blockade has improved the prognosis of recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC), but response rates remain low. In this study, we aimed to investi...
Clinical characteristics of liver injury induced by immune checkpoint inhibitors in patients with advanced biliary tract carcinoma [0.03%]
免疫检查点抑制剂诱导的晚期胆道癌患者肝损伤的临床特征分析
Zhao Gao,Shikai Wu,Yinmo Yang et al.
Zhao Gao et al.
Immune-related liver injuries are closely associated with the liver's fundamental state. Patients with advanced biliary tract carcinoma (BTC) have poor liver function. We evaluated the clinical data of immune-related liver injury in patient...
Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma [0.03%]
阿卡比珠玛单抗和伊沙珠玛单抗治疗难治或复发性滤泡性淋巴瘤的疗效、安全性和最小成本分析
Buthainah Ghanem
Buthainah Ghanem
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are chimeric antigen receptor (CAR) T-cell therapies used to treat adult patients with relapsed or refractory follicular lymphoma (rrFL) after two or more lines of systemic t...
Preclinical evaluation of the VEGF/Ang2 bispecific nanobody BI 836880 in nasopharyngeal carcinoma models [0.03%]
鼻咽癌模型中针对VEGF/Ang2双特异纳米抗体BI 836880的药物非临床评估研究
Rachel C T Lam,Connie W C Hui,C H Wong et al.
Rachel C T Lam et al.
Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) is endemic to parts of Asia and overexpression of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1α are common in NPC. Anti-vascular agents have kno...
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study [0.03%]
用于既往治疗后的子宫内膜癌患者的 lurbinectedin：来自篮子临床试验和探索性转化研究的结果
Rebecca Kristeleit,Alexandra Leary,Jean Pierre Delord et al.
Rebecca Kristeleit et al.
Second-line treatment of endometrial cancer is an unmet medical need. Lurbinectedin showed promising antitumor activity in a phase I study in combination with doxorubicin in advanced endometrial cancer. This phase 2 Basket trial evaluated l...
Gabriel Gallo-Oller,Teresita Díaz de Ståhl,Ayodele Alaiya et al.
Gabriel Gallo-Oller et al.
Medulloblastoma (MB) is the most common pediatric brain tumor. The therapy frequently causes serious side effects, and new selective therapies are needed. MB expresses hyper sialylation, a possible target for selective therapy. The cytotoxi...
Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation [0.03%]
vegfr2靶向免疫脂质体联合激活nk细胞的抗肿瘤和抗转移作用增强效应
Mingzhu Pan,Yali Liu,Tian Sang et al.
Mingzhu Pan et al.
Liposomal doxorubicin exhibits stronger drug accumulation at the tumor site due to the Enhanced Permeability and Retention (EPR) effect. However, the prognosis for the patient is poor due to this drug's lack of targeting and tumor metastasi...
Development and characterization of fused human arginase I for cancer therapy [0.03%]
用于癌症治疗的融合人精氨酸酶I的开发与表征
Snehal Sainath Jawalekar,Priyanka Sugriv Kawathe,Nisha Sharma et al.
Snehal Sainath Jawalekar et al.
Recombinant human arginase I (rhArg I) have emerged as a potential candidate for the treatment of varied pathophysiological conditions ranging from arginine-auxotrophic cancer, inflammatory conditions and microbial infection. However, rhArg...
Development of novel palbociclib-based CDK4/6 inhibitors exploring the back pocket behind the gatekeeper [0.03%]
基于Palbociclib的新型CDK4/6抑制剂的开发，探索守门者背后的口袋区域
Lina Li,Fengquan Chen,Mengzhe Li et al.
Lina Li et al.
CDK4/6 inhibitors plus endocrine therapy is a standard therapy for HR+/HER2- breast cancer. Herein, using structure-based drug design strategy, a novel series of palbociclib derivatives were designed and synthesized as CDK4/6 inhibitors, am...
Pharmacological assessment of the antineoplastic and immunomodulatory properties of a new spiroindolone derivative (7',8'-Dimethoxy-1',3'-dimethyl-1,2,3',4'-tetrahydrospiro[indole-3,5'-pyrazolo[3,4-c]isoquinolin]-2-one) in chronic myeloid leukemia [0.03%]
评估一种新的Spiroindolone衍生物（7 ',8'-Dimethoxy-1',3'-dimethyl-1,2,3',4'-tetrahydrospiro[indole-3,5'-pyrazolo[3,4-c]isoquinolin]-2-one)在慢性粒细胞性白血病中的抗肿瘤和免疫调节药理学性质
Carlos Eduardo de Castro Alves,Serge L Bogza,Nathalie Bohdan et al.
Carlos Eduardo de Castro Alves et al.
The discovery and development of effective novel compounds is paramount in oncology for improving cancer therapy. In this study, we developed a new derivative of spiroindolone (7',8'-Dimethoxy-1',3'-dimethyl-1,2,3',4'-tetrahydrospiro[indole...